Chinese expert consensus on targeted and immunotherapy combined with concurrent chemoradiotherapy in the treatment of locally advanced cervical cancer
10.3760/cma.j.cn113030-20240305-00087
- VernacularTitle:靶向及免疫药物联合同步放化疗治疗局部晚期宫颈癌中国专家共识
- Author:
Ping JIANG
1
;
Zi LIU
;
Lichun WEI
;
Yunyan ZHANG
;
Fengju ZHAO
;
Xiangkun YUAN
;
Yipeng SONG
;
Jing BAI
;
Xiaofan LI
;
Baosheng SUN
;
Lijuan ZOU
;
Sha LI
;
Yuhua GAO
;
Yanhong ZHUO
;
Song GAO
;
Qin XU
;
Xiaohong ZHOU
;
Hong ZHU
;
Junjie WANG
Author Information
1. 北京大学第三医院肿瘤放疗科，北京 100191
- Keywords:
Uterine cervical neoplasms;
Locally advanced;
Targeted therapy;
Immunotherapy;
Concurrent chemoradiotherapy
- From:
Chinese Journal of Radiation Oncology
2024;33(10):893-901
- CountryChina
- Language:Chinese
-
Abstract:
Concurrent chemoradiotherapy (CCRT) refers to the simultaneous treatment of chemotherapy and radiotherapy, and the effect of radiotherapy is enhanced with low-dose chemotherapy, which can reduce tumor recurrence and metastasis and improve clinical prognosis of patients. At present, the main factors for the increase of radiosensitivity of concurrent chemotherapy is that concurrent chemotherapy prevents the repair of tumor cells, and chemotherapy and radiotherapy act on different cell cycles and have synergistic effects. However, even for patients with locally advanced cervical cancer (LACC) who have undergone CCRT, the 5-year survival rate is only 60%, which is still not ideal. In order to improve the efficacy, researchers have conducted a series of exploratory studies, which consist of the combination of targeted drugs and immunodrugs, and neoadjuvant regimens before CCRT, etc. Although targeted or immunologic drugs are effective treatment of LACC, in view of the lack of large-scale evidence-based medical evidence, multi-center prospective and randomized phase III clinical trials and high-level articles are needed to improve the level of evidence-based medicine. This consensus summarizes several key evidence-based medical studies published recently, especially the clinical research progress in targeted and immunological therapies, providing reference for domestic peers.
